IgA Nephropathy
IgA Nephropathy
Advertisement
Charlotte RobinsonIgA Nephropathy | June 19, 2024
The American Kidney Fund has launched the Rare Kidney Disease Action Network.
Read More
Ajay K. Singh, MBBS, FRCP, MBAIgA Nephropathy | June 4, 2024
IgA nephropathy (IgAN) is on the cusp of a transformational change in its treatment.
Charlotte RobinsonIgA Nephropathy | May 29, 2024
The FDA has granted Breakthrough Therapy Designation to atacicept to treat IgA nephropathy (IgAN).
Victoria SochaIgA Nephropathy | May 2, 2024
Researchers studied the effect of intensive blood pressure control on the progression of IgAN. 
Charlotte RobinsonIgA Nephropathy | April 26, 2024
FILSPARI (sparsentan) has received conditional marketing authorization from the European Commission to treat IgAN in adults.
Charlotte RobinsonWCN 2024 | April 30, 2024
Interim analysis from the APPLAUSE-IgAN trial found favorable results for the use of iptacopan in IgAN.
Charlotte RobinsonWCN 2024 | April 19, 2024
Longer follow-up results of the RUBY-3 trial found povetacicept is well-tolerated and shows promise for IgAN treatment.
Charlotte RobinsonWCN 2024 | April 18, 2024
Researchers found that sparsentan had a clinically meaningful benefit on long-term kidney preservation versus irbesartan.
Charlotte RobinsonIgA Nephropathy | April 12, 2024
Vertex Pharmaceuticals will acquire Alpine Immune Sciences, developer of povetacicept for IgA nephropathy.
Charlotte RobinsonIgA Nephropathy | April 12, 2024
Results from a trial of atacicept for the treatment of IgAN will be presented at the European Renal Association Congress.
Charlotte RobinsonIgA Nephropathy | April 12, 2024
Results of the RUBY-3 study of povetacicept for IgAN will be presented at the ISN World Congress of Nephrology.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | April 12, 2024
APRIL has emerged as a critical factor in the pathogenesis of IgAN and is the focus of several clinical development programs.
Dr. Richard LafayetteIgA Nephropathy | May 29, 2024
Dr. Richard Lafayette discusses the FDA approval of TARPEYO as treatment for adults with IgA nephropathy.
Victoria SochaIgA Nephropathy | October 11, 2023
Worldwide, immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis.
Victoria SochaIgA Nephropathy | October 11, 2023
Clinical manifestations associated with IgAN include hematuria, proteinuria, and hypertension.
Victoria SochaIgA Nephropathy | June 28, 2023
Where patients reported nausea/vomiting, it was not recognized by nephrologists in 85% of cases.
Victoria SochaIgA Nephropathy | June 28, 2023
Worldwide, immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis.
Victoria SochaNephrology Times | December 16, 2021
The FDA has granted accelerated approval for Tarpeyo (budesonide) delayed release capsules to reduce proteinuria ...
DocWire News EditorsIgA Nephropathy | October 25, 2021
A study sought to discern surrogate endpoints that could serve as robust predictors of treatment efficacy on long-term ...
DocWire News EditorsIgA Nephropathy | October 25, 2021
A study shows that sustained proteinuria is a strong predictor for the rate of progression of renal disease, and ...
Advertisement
Advertisement
Advertisement
Latest News

July 12, 2024